Yun Choi

Fixed-treatment duration venetoclax following covalent BTKi progression in chronic lymphocytic leukemia

Isabelle Fleury, Brian T. Hill, Toby Andrew Eyre, Chaitra Shankar Ujjani et autres

Covalent Bruton tyrosine kinase inhibitors (cBTKis) are commonly used targeted agents in early lines of therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) 1,2 ; however, treatment following disease progression on cBTKis remains a challenge in clinical practice.3,4 Venetoclax …

ca, us, gb (code pays fourni par la source)

Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma

Sanjal H. Desai, Susan M. Geyer, Levi Pederson, Michael A. Spinner et autres

Patients with classic Hodgkin lymphoma (cHL) with primary refractory disease, early relapse, or extranodal disease have a higher risk of relapse after salvage therapy and autologous stem cell transplant (ASCT). Post-ASCT brentuximab vedotin (BV) maintenance improved progression-free survival (PFS) in high-risk relapsed/refractory …

us, cz (code pays fourni par la source)

Safety and Immunomodulatory Effects of Siltuximab Prophylaxis Prior to Standard of Care CD19 Directed Chimeric Antigen Receptor T-cell (CD19.CART) Therapy for B-cell Lymphomas: Final Phase I Trial Results

Nathan Denlinger, NoJoon Song, Negin Goodarzi, Rina Li Welkie et autres

Introduction CD19.CART is highly effective for B-cell non-Hodgkin lymphomas (NHL). However, CRS and ICANS remain a challenge. Interleukin-6 (IL-6) is a mediator of CRS/ICANS. Siltuximab (siltux), an IL-6 antagonist, has efficacy in treating CRS/ICANS (Bajwa, Blood Advances, 2025) and has been shown …

Anti-CD19 Chimeric Antigen Receptor T-cell Therapy for Patients with Non-Hodgkin's Lymphoma and Concurrent Autoimmune Disease

Zachary Braunstein, Zeynep Ozgur, Eric M. McLaughlin, Timothy J. Voorhees et autres

Introduction CD19 targeted chimeric antigen receptor T cell therapy (CART) is standard of care (SOC) treatment (tx) for relapsed/refractory (r/r) B-cell non-Hodgkin's Lymphoma (NHL). Patients (pts) with r/r NHL and concurrent autoimmune diseases (AID) are often excluded from clinical trials, and the …

Sustained Expansion of CAR-Negative T cells Correlates with Improved Outcomes after CD19 CAR T-cell Therapy in Lymphoma

Jiasheng Wang, Tuan L. Phan, Timothy J. Voorhees, David Alan Bond et autres